Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Nvidia Options Price in $280 Billion Earnings Swing 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Trump Buys SpaceX Shares After Record IPO 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Add as a preferred source on Google
WESTLAKE VILLAGE, Calif., May 02, 2018 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To view and listen to the earnings call webcast live via the Internet, visit the Company's website at www.mannkindcorp.com and click on the “Q1 2018 MannKind Earnings Conference Call” link in the Webcasts section of News & Events. To participate in the live call by telephone, please dial (800) 289-0438 toll-free or (323) 794-2423 toll/international and use the conference passcode: 3321662.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 toll-free or (412) 317-6671 toll/international and use the replay passcode: 3321662. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[email protected]
